BP
LLY icon

Ballentine Partners’s Eli Lilly LLY Stock Holding History

Ballentine Partners’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.2M Buy
20,150
+273
+1% +$279K 0.3% 40
2026
Q1 		$18.3M Buy
19,877
+480
+2% +$487K 0.25% 45
2025
Q4 		$20.8M Buy
19,397
+481
+3% +$460K 0.29% 41
2025
Q3 		$14.4M Buy
18,916
+1,332
+8% +$991K 0.2% 47
2025
Q2 		$13.7M Sell
17,584
-369
-2% -$287K 0.21% 46
2025
Q1 		$14.8M Buy
17,953
+693
+4% +$577K 0.26% 40
2024
Q4 		$13.3M Buy
17,260
+279
+2% +$231K 0.23% 43
2024
Q3 		$15M Buy
16,981
+601
+4% +$540K 0.26% 40
2024
Q2 		$14.8M Buy
16,380
+1,145
+8% +$916K 0.27% 40
2024
Q1 		$11.9M Buy
15,235
+1,442
+10% +$1.03M 0.23% 44
2023
Q4 		$8.04M Buy
13,793
+1,069
+8% +$624K 0.16% 50
2023
Q3 		$6.83M Buy
12,724
+372
+3% +$192K 0.16% 51
2023
Q2 		$5.79M Buy
12,352
+632
+5% +$265K 0.13% 56
2023
Q1 		$4.02M Buy
11,720
+4,697
+67% +$1.58M 0.1% 79
2022
Q4 		$2.57M Buy
7,023
+494
+8% +$175K 0.08% 95
2022
Q3 		$2.11M Buy
6,529
+1,410
+28% +$447K 0.07% 93
2022
Q2 		$1.66M Buy
5,119
+555
+12% +$167K 0.06% 111
2022
Q1 		$1.31M Buy
4,564
+450
+11% +$116K 0.04% 146
2021
Q4 		$1.14M Buy
4,114
+340
+9% +$86.2K 0.03% 165
2021
Q3 		$872K Buy
3,774
+48
+1% +$11.8K 0.03% 171
2021
Q2 		$855K Sell
3,726
-40
-1% -$8.04K 0.03% 168
2021
Q1 		$704K Buy
3,766
+50
+1% +$9.78K 0.03% 182
2020
Q4 		$627K Sell
3,716
-1,560
-30% -$233K 0.02% 190
2020
Q3 		$781K Buy
5,276
+271
+5% +$41.9K 0.03% 160
2020
Q2 		$821K Buy
5,005
+82
+2% +$12.6K 0.04% 155
2020
Q1 		$683K Buy
4,923
+585
+13% +$80.4K 0.04% 156
2019
Q4 		$570K Buy
4,338
+74
+2% +$8.58K 0.03% 209
2019
Q3 		$477K Sell
4,264
-63
-1% -$7.01K 0.02% 212
2019
Q2 		$480K Buy
4,327
+771
+22% +$90.8K 0.02% 219
2019
Q1 		$461K Buy
3,556
+207
+6% +$25.2K 0.02% 196
2018
Q4 		$387K Sell
3,349
-1,391
-29% -$155K 0.02% 208
2018
Q3 		$509K Buy
4,740
+122
+3% +$12.2K 0.03% 197
2018
Q2 		$394K Buy
4,618
+43
+0.9% +$3.53K 0.02% 216
2018
Q1 		$354K Sell
4,575
-567
-11% -$45.6K 0.02% 239
2017
Q4 		$435K Buy
5,142
+172
+3% +$14.6K 0.02% 208
2017
Q3 		$426K Buy
4,970
+2,004
+68% +$164K 0.02% 213
2017
Q2 		$243K Sell
2,966
-108
-4% -$8.81K 0.02% 311
2017
Q1 		$259K Buy
+3,074
New +$246K 0.02% 201
2016
Q4 		– Sell
-3,004
Closed -$240K – 219
2016
Q3 		$240K Sell
3,004
-1,758
-37% -$141K 0.02% 164
2016
Q2 		$374K Sell
4,762
-139
-3% -$10.5K 0.03% 137
2016
Q1 		$354K Buy
4,901
+2,094
+75% +$158K 0.03% 139
2015
Q4 		$236K Buy
2,807
+209
+8% +$17.3K 0.02% 157
2015
Q3 		$218K Buy
2,598
+162
+7% +$13.7K 0.02% 147
2015
Q2 		$204K Buy
+2,436
New +$186K 0.02% 154

Other funds holding LLY

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
ONB
Old National Bancorp Evansville, Indiana $5.02B AUM 25.65% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
GIM
Goelzer Investment Management Carmel, Indiana $2.29B AUM 39.12% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
CRM
Cardano Risk Management Rotterdam, Netherlands $13B AUM 49.44% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Ballentine Partners's LLY Position: Q2 2026 in Review

Ballentine Partners increased its Eli Lilly (LLY) stake by 1.4% in Q2 2026, buying an estimated $279K and bringing the position to 20,150 shares worth $24.2M. The position accounts for 0.3% of the portfolio, ranked #40.

Ballentine Partners first reported a position in LLY in Q2 2015 and has held it in 44 quarters since. 841 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Ballentine Partners held 20,150 shares of Eli Lilly worth $24.2M as of Q2 2026.
  • Ballentine Partners bought 273 Eli Lilly shares in Q2 2026, an estimated $279K.
  • Eli Lilly made up 0.3% of Ballentine Partners's portfolio in Q2 2026, its #40 holding.
  • Ballentine Partners first reported a position in Eli Lilly in Q2 2015 and has held it in 44 quarters since.
  • 841 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.